STAAR Surgical Company reported that its stockholders did not approve the proposed merger agreement with Alcon at a recent special meeting. As a result, STAAR plans to terminate the agreement, with no termination fee required from either party. The company will remain independent and continue to operate as a publicly traded entity on Nasdaq under the ticker symbol "STAA." CEO Stephen Farrell stated that STAAR will focus on maximizing stockholder value and expanding the use of its EVO ICL technology worldwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106924852) on January 06, 2026, and is solely responsible for the information contained therein.
Comments